Shares in GC Green Cross Wellbeing surged 8.48% to 14,840 won by 10 a.m. on May 7 at the Korea Exchange, driven by a new supply contract with Japanese partner Nifuji for its GCELLE REBORNNE skin booster. This deal marks a key step in the company's push into Asia's premium aesthetics market, where demand for advanced tissue-derived treatments grows steadily. The agreement promises stable distribution and joint marketing efforts in Japan, a market prized for its regulatory rigor and consumer sophistication.
Product Innovation at the Core
GCELLE REBORNNE relies on human acellular dermal matrix (hADM), a biomaterial processed from human tissue to remove cells while preserving the extracellular matrix. This structure enhances biocompatibility, allowing the skin booster to integrate smoothly and stimulate natural regeneration with minimal damage or rejection risks. Unlike synthetic fillers, hADM mimics the body's own scaffolding, supporting applications in anti-aging and wound healing that appeal to dermatologists and aesthetic clinics.
Strategic Footprint in Japan
Supply of GCELLE REBORNNE to Japan began in March, aligning with its domestic launch in South Korea. GC Green Cross Wellbeing now plans a May symposium for Japanese medical professionals to build awareness through academic channels. Partner Nifuji provides an established network, addressing Japan's strict standards for imported biologics and positioning the product for broader adoption in a market that values evidence-based cosmetics.
Global Ambitions Built on Proven Expertise
The company views Japan as a launchpad for Asian and worldwide expansion, drawing on experience with Laennec, its established human placenta-derived pharmaceutical. A company official highlighted this track record: "We have the know-how from successfully establishing Laennec in the market. We will continue to expand our position in the Asian market based on our differentiated technology." This approach emphasizes local partnerships to navigate regulations and cultural preferences, fueling growth in the global biologics sector projected to expand as consumers seek safer, more effective skin rejuvenation options.
